ST Pharm Co.,Ltd. (KOSDAQ:237690)

South Korea · Delayed Price · Currency is KRW

135,000

+17,600 (14.99%)

Jun 29, 2026, 3:30 PM KST

76.47% (1Y)

Market Cap	2.82T +76.5%
Revenue (ttm)	346.22B +26.2%
Net Income	69.01B +133.8%
EPS	3,312.63 +122.5%
Shares Out	20.87M
PE Ratio	40.75
Forward PE	37.16
Dividend	500.00 (0.43%)
Ex-Dividend Date	Mar 30, 2026

Volume	321,844
Open	118,000
Previous Close	117,400
Day's Range	118,000 - 137,100
52-Week Range	76,100 - 172,100
Beta	0.22
Analysts	Strong Buy
Price Target	197,000.00 (+45.93%)
Earnings Date	Jul 27, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 1983

Employees 655

Stock Exchange KOSDAQ

Ticker Symbol 237690

Full Company Profile

Financial Performance

In 2025, ST Pharm's revenue was 331.68 billion, an increase of 21.16% compared to the previous year's 273.75 billion. Earnings were 54.99 billion, an increase of 58.42%.

Financial Statements

Analyst Summary

According to 10 analysts, the average rating for 237690 stock is "Strong Buy." The 12-month stock price target is ₩197,000, which is an increase of 45.93% from the latest price.

Price Target

₩197,000

(45.93% upside)

Analyst Consensus: Strong Buy

Stock Forecasts